Intrauterine Devices Market Size & Growth Forecast 2027–2036, By Segments (Type, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Intrauterine Devices Market size stood at USD 6.9 billion in 2026 and is predicted to grow at a 3.52% CAGR from 2027 to 2036, crossing USD 9.75 billion by 2036. The industry revenue for 2027 is estimated at USD 7.1 billion.

• Base Year Value (2026): USD 6.9 billion
• CAGR (2027-2036): 3.52%
• Forecast Year Value (2036): USD 9.75 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Intrauterine Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to established reproductive healthcare services, broad access to trained providers, and strong adoption of long-acting reversible contraception through clinical care settings.
  • Asia Pacific is projected to expand at a 4.33% CAGR, driven by improving women's healthcare access, wider contraceptive adoption, and expanding provider networks supporting family planning services.

• Segment Momentum:

  • Hormonal IUD held a 70.07% share in 2026, supported by widespread clinical familiarity and strong demand for reliable, long-acting, reversible contraception requiring minimal ongoing patient involvement.
  • Gynecology clinics are growing fastest because they provide specialized contraceptive counseling, insertion, and follow-up services, offering streamlined access that aligns well with routine IUD care and patient management.

• Market Expansion Drivers:

  • Government family planning initiatives increasing adoption of long-acting contraceptive solutions.
  • Rising awareness and education programs improving acceptance of intrauterine contraceptive devices.
  • Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options.

• Leading Market Participants:

  Prominent players in the intrauterine devices market include Bayer AG (Germany), CooperSurgical Inc. (United States), Pregna International Limited (India), EUROGINE, S.L. (Spain), OCON Medical Ltd. (Israel), Mona Lisa N.V. (Belgium), SMB Corporation of India (India), AbbVie Inc. (United States), DKT International (United States), Prosan International BV (Netherlands).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 6.9 billion
  • 2027 Estimated Market Size: USD 7.1 billion.
  • Projected Market Size: USD 9.75 billion by 2036
  • Growth Forecasts: 3.52% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hormonal IUD (Type) | Hospital (Distribution Channel)
  • Emerging Opportunity Segment: Hormonal IUD (Type) | Gynecology Clinics (Distribution Channel)

Market Growth Drivers and Industry Trends

Government family planning initiatives increasing adoption of long-acting contraceptive solutions

Public-sector family planning programs are strengthening intrauterine devices market growth by improving access to long-acting contraceptive methods through awareness campaigns, healthcare services, and reproductive health initiatives. Governments and public health systems can encourage the use of long-acting options by integrating contraceptive counseling and device provision into maternal, reproductive, and primary healthcare services, particularly in regions where reducing unintended pregnancies is a policy priority. Greater availability through public facilities and trained healthcare professionals can also lower practical barriers to adoption, while the long-duration nature of IUDs makes them an attractive option for individuals seeking reliable contraception without the need for frequent administration.

Rising awareness and education programs improving acceptance of intrauterine contraceptive devices

Improved patient education is supporting intrauterine devices market demand by addressing misconceptions surrounding insertion, effectiveness, side effects, and long-term use. Awareness initiatives delivered through healthcare providers, community programs, educational materials, and reproductive health counseling can give individuals clearer information for evaluating different contraceptive choices and understanding the suitability of IUDs for their circumstances. As accurate information becomes more accessible, greater familiarity with the procedure and device characteristics can reduce hesitation among potential users, while informed counseling enables healthcare professionals to match contraceptive options with individual preferences and reproductive goals.

Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options

Technological development in hormone-free intrauterine contraception is creating additional opportunities within the intrauterine devices market by addressing demand from users who prefer to avoid hormonal contraceptive methods. Newer device concepts can focus on improving contraceptive performance, user comfort, insertion characteristics, and duration of use while maintaining a non-hormonal approach. This innovation expands the range of options available to individuals who may have concerns about hormonal exposure or prefer a hormone-free method, while continued refinement of device design can support broader acceptance among patients and healthcare professionals.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Government family planning initiatives increasing adoption of long-acting contraceptive solutions	1.80%	High	Asia Pacific, Africa, Latin America	High	Near Term
Rising awareness and education programs improving acceptance of intrauterine contraceptive devices	1.50%	Moderate	Asia Pacific, Europe	High	Mid Term
Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options	1.30%	High	North America, Europe	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of the intrauterine devices market in 2026, supported by established reproductive healthcare infrastructure, broad access to contraceptive services, and increasing awareness of long-acting reversible contraception. Healthcare providers increasingly recognize intrauterine devices as effective options for patients seeking reliable, low-maintenance contraception, supporting their integration into routine family-planning services. Continued attention to reproductive health education, patient counseling, and access to modern contraceptive methods is further reinforcing regional demand.

Asia Pacific is experiencing the fastest growth in the intrauterine devices market as healthcare systems expand access to family-planning services and awareness of long-acting contraception improves. Rising healthcare investment, broader availability of reproductive health services, and initiatives aimed at improving maternal and reproductive care are creating new opportunities for adoption. Increasing urbanization and greater consumer awareness of contraceptive choices are also supporting demand, particularly as healthcare delivery becomes more accessible across developing markets.

Key Country Insights

United States

Women's Health Innovation

The U.S. intrauterine devices market emphasizes expanding access to long-acting reversible contraception through advanced product options and broader provider adoption. Healthcare organizations in the U.S. continue supporting patient education and streamlined reproductive healthcare services.

Japan

Personalized Contraceptive Care

Japan is gradually expanding the use of intrauterine devices by improving physician awareness and individualized contraceptive counseling. Medical providers in Japan are focusing on patient education and appropriate device selection for long-term reproductive health management.

South Korea

Preventive Women's Healthcare

South Korea is strengthening the intrauterine devices market through broader reproductive health awareness and expanding access to modern contraceptive methods. Healthcare institutions in South Korea continue promoting clinician training and patient-centered family planning services.

Germany

Clinical Care Integration

Germany prioritizes intrauterine device adoption through standardized gynecological care and evidence-based contraceptive practices. Healthcare providers in Germany continue integrating modern IUD options into preventive women's health services with a focus on long-term patient outcomes.

France

Reproductive Care Accessibility

France supports intrauterine device utilization through comprehensive reproductive healthcare services and preventive care programs. Healthcare professionals in France continue encouraging informed contraceptive choices while expanding access to long-acting reversible contraceptive solutions.

Italy

Gynecological Practice Support

Italy is advancing the intrauterine devices market by strengthening women's healthcare services and improving clinical adoption of long-term contraception. Italian healthcare providers emphasize patient consultation and reliable contraceptive solutions within routine gynecological practice.

Segment Leadership and Growth Trends

 

Type Segment Analysis: Hormonal IUD (Largest & Fastest-Growing Segment)

The hormonal IUD segment dominated the intrauterine devices market, holding 70.07% of the market share in 2026, while also representing the fastest-growing type. Its strong position is supported by the combination of long-term contraceptive effectiveness, convenience, and localized hormone delivery, which can also provide benefits such as reduced menstrual bleeding for suitable users. Growing awareness of long-acting reversible contraception and greater preference for low-maintenance birth control options continue to support adoption.

Distribution Channel Segment Analysis: Hospital (Largest Segment) vs Gynecology Clinics (Fastest-Growing Segment)

The hospital segment accounted for the largest share of 57.16% in 2026, reflecting the important role of hospital-based reproductive healthcare services in counseling, device selection, insertion, and follow-up care. Hospitals offer access to specialized clinical expertise and comprehensive gynecological services, supporting their continued relevance for patients seeking professionally administered contraceptive procedures.

Gynecology clinics are the fastest-growing distribution channel as patients increasingly seek specialized, accessible, and more personalized reproductive health services. Dedicated clinics can provide focused contraceptive counseling, streamlined insertion procedures, and follow-up care, while growing awareness of long-acting contraceptive options is supporting greater utilization through these settings.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Hormonal IUD, Copper IUD	Hormonal IUD	Hormonal IUD
Distribution Channel	Hospital, Gynecology Clinics, Community Health Care Centers, Others	Hospital	Gynecology Clinics

Competitive Landscape and Market Positioning

Leading companies in the intrauterine devices market:

1. Bayer AG (Germany)

2. CooperSurgical Inc. (United States)

3. Pregna International Limited (India)

4. EUROGINE S.L. (Spain)

5. OCON Medical Ltd. (Israel)

6. Mona Lisa N.V. (Belgium)

7. SMB Corporation of India (India)

8. AbbVie Inc. (United States)

9. DKT International (United States)

10. Prosan International BV (Netherlands)

The intrauterine devices market is advancing with improvements in contraceptive design and long-term effectiveness. Continuous innovation is enhancing safety, comfort, and ease of use. New product introductions are addressing diverse reproductive health needs across populations. The intrauterine devices market is growing with increased adoption of reliable and minimally invasive contraceptive solutions.

Industry Development/News

Company Name	Date	Key Development
Society for Family Health	May-26	Society for Family Health, in collaboration with the Oyo State Primary Health Care Board, conducted a dissemination meeting for the SHINE Research initiative focused on scaling hormonal intrauterine devices. The program evaluated implementation outcomes and strategies to expand access to hormonal IUDs in emerging markets.
Bayer AG	Aug-22	Bayer AG received FDA approval for a supplemental new drug application extending the use duration of its Mirena IUD to up to eight years. The approval strengthens its long-acting contraceptive portfolio and enhances product lifecycle positioning within the hormonal intrauterine device segment.
Medicines360	Jan-24	Medicines360 partnered with DKT WomanCare to expand access to AVIBELA, a hormonal intrauterine device with high contraceptive effectiveness. The collaboration focuses on improving distribution, affordability, and awareness of long-acting reversible contraceptive options across global markets.
Pregna International Limited	Jun-23	Pregna International Limited secured a USD 16 million private equity investment from India Life Sciences Fund III managed by InvAscent. The funding is intended to support expansion and development of women’s reproductive health solutions, including intrauterine device offerings.
Sebela Pharmaceuticals	Feb-25	Sebela Pharmaceuticals received FDA approval for MIUDELLA, a contraceptive product indicated for pregnancy prevention in females of reproductive potential for up to three years. The approval expands the company’s reproductive health portfolio and strengthens its position in the long-acting contraceptive market.
Bayer	Nov-23	Bayer entered a collaboration and licensing agreement with CrossBay Medical Inc. to develop a single-handed inserter integrated with its hormonal intrauterine system portfolio. The initiative aims to improve device usability for healthcare providers and enhance product differentiation in the IUD market.
CooperSurgical, Inc.	Sep-24	CooperSurgical introduced a new single-hand inserter for Paragard, a hormone-free copper intrauterine device. The device launch improves ease of placement for clinicians and strengthens the usability and procedural efficiency of non-hormonal IUD insertion systems.
Medicines360	Mar-22	Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing IUS) in Nigeria. The initiative expanded access to hormonal intrauterine contraception in West Africa through coordinated distribution and public health partnerships.
Medicines360	Aug-21	Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing IUS) in Kenya. The rollout supported expansion of long-acting reversible contraceptive access in East Africa through multi-stakeholder public health collaboration.
Society for Family Health	May-26	Society for Family Health, in collaboration with health authorities and partners, conducted an end-of-project dissemination for the SHINE initiative focused on scaling hormonal intrauterine devices. The program evaluated implementation outcomes and supported evidence generation for expanding access to hormonal IUDs in emerging healthcare markets.
Sebela Pharmaceuticals	Feb-25	The U.S. FDA approved Sebela Pharmaceuticals’ MIUDELLA intrauterine system for pregnancy prevention for up to three years. This regulatory approval expands the company’s hormonal IUD portfolio and strengthens its competitive position in long-acting reversible contraceptive solutions within the U.S. reproductive health market.
Medicines360	Jan-24	Medicines360 and DKT WomanCare partnered to expand access to the AVIBELA hormonal intrauterine device across global markets. The collaboration focuses on improving affordability, distribution reach, and awareness of long-acting reversible contraception, strengthening supply availability in underserved reproductive health segments.
Bayer AG	Nov-23	Bayer and CrossBay Medical entered a licensing and development agreement to create a single-handed inserter for Bayer’s hormonal intrauterine system portfolio. The initiative enhances usability for healthcare providers and strengthens Bayer’s competitive positioning through improved device delivery and procedural efficiency in IUD administration.
Pregna International Limited	Jun-23	Pregna International Limited secured a USD 16 million private equity investment from India Life Sciences Fund III managed by InvAscent. The funding is intended to support expansion in women’s reproductive health product development and scale manufacturing and commercialization capabilities for intrauterine device solutions across global markets.
Bayer AG	Aug-22	Bayer received FDA supplemental approval extending the use duration of its Mirena intrauterine device to up to eight years. This regulatory update strengthens product lifecycle positioning and enhances long-term competitiveness in the hormonal IUD segment by expanding patient usage flexibility and clinical adoption potential.
CooperSurgical Inc.	Sep-24	CooperSurgical introduced a new single-hand inserter for its Paragard copper intrauterine device. The device is designed to improve procedural ease and placement efficiency in clinical settings, supporting enhanced usability for healthcare providers and reinforcing adoption of hormone-free IUD solutions in contraceptive care.